David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, shared a post on LinkedIn:
“Antibody-drug conjugates are transforming NSCLC, but biomarkers remain the missing piece of the puzzle.
Targeting TROP2, New data/ICARUS-LUNG01 (Dato-DXd) and key biomarkers:
- Response: Associated with immune pathway activation, non-squamous NSCLC
- Resistance: Linked to low TROP2 cytoplasmic expression and DNA repair pathways
Thank you to the patients, families, investigators, and Daiichi-Sankyo who made ICARUS-LUNG01 possible!”
Title: Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study
Authors: David Planchard, Nathalie Cozic, Maria Fernanda Mosele, Noemie Corcos, Loic Le Bescond, Yoann Pradat, Maria Rosa Ghigna, Ghada Nachabeh, Alexia Alfaro, Cyril Catelain, Bastien Job, Fathia Mami-Chouaib, Severine Badel, Stephanie Corgnac, Françoise Farace, Marianne Oulhen, Patricia Kannouche, Diep Thi Ngoc Tran, Nathalie Droin, Marie Wislez, Christos Chouaid, Hubert Curcio, Sophie Cousin, Celine Mascaux, Jacques Cadranel, Margaux Geier, Rasha Cheikh-Hussin, Pierre Guyader, Nicholas Signolle, Karine Godefroy, Hugues Talbot, Maria Vakalopoulou, Stergios Christodoulidis, Elsa Bernard, Yves Koudou, Valerie Camara, Abdelhafidh Belarkemi, Alexis Klein, Jean Philippe Morretton, Philip East, Rachel Chiaverelli, Ricardo Zwirtes, Stefan Michiels, Fabrice Barlesi, Fabrice André, Guillaume Montagnac, Barbara Pistilli
Read the Full Article.
